13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001826434
Total reported value
$813.2M
$813.2M
28 檔
23.1%
As reported in its official Q4 2024 Form 13F filing, Tri Locum Partners LP's tracked investment portfolio stood at $813.2M with 28 total positions.
In Q4 2024, Tri Locum Partners LP displayed an active expansion posture, initiating 12 new positions and adding to 7 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 11.06% | -1.21% | -12.07% | |
| 2 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 8.07% | — | — | |
| 3 | ARGX | Argenx Se - Adr | Stock-Healthcare | 7.42% | +1.51% | -6.75% | |
| 4 | NTRA | Natera Inc | Stock-Healthcare | 6.65% | — | -36.16% | |
| 5 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 5.79% | — | -0.42% | |
| 6 | STVN | Stevanato Group S.p.A. | Stock-Other | 5.06% | — | -39.94% | |
| 7 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 4.38% | +5.13% | +172.31% | |
| 8 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.37% | — | -23.53% | |
| 9 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 4.22% | — | +16.68% | |
| 10 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 4.16% | — | — | |
| 11 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 4.13% | +2.36% | — | |
| 12 | IDXX | Idexx Laboratories Inc | Stock-Healthcare | 3.85% | — | — | |
| 13 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 3.74% | — | +212.21% | |
| 14 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 3.03% | -3.08% | +9.67% | |
| 15 | ✓ | Merus N V | Stock-Other | 3.03% | — | +80.74% | |
| 16 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 2.95% | — | — | |
| 17 | JANX | Janux Therapeutics Inc | Stock-Other | 2.62% | — | — | |
| 18 | LEGN | Legend Biotech Corp-adr | Stock-Other | 2.62% | — | +7.30% | |
| 19 | CI | THE Cigna Group | Stock-Healthcare | 2.33% | — | — | |
| 20 | WGS | Genedx Holdings CORP | Stock-Other | 2.03% | — | — | |
| 21 | GERN | Geron CORP | Stock-Other | 1.81% | — | — | |
| 22 | EOLS | Evolus Inc | Stock-Other | 1.70% | — | — | |
| 23 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.18% | — | -50.64% | |
| 24 | KRRO | Korro Bio Inc | Stock-Other | 1.14% | — | +125.29% | |
| 25 | BHVN | Biohaven Ltd. | Stock-Other | 1.08% | — | -27.42% | |
| 26 | LIVN | LivaNova PLC | Stock-Other | 0.96% | — | — | |
| 27 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.59% | — | — | |
| 28 | ✓ | Femasys Inc | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ZBH | Zimmer Biomet Holdings Inc | +8.1% | NEW | New buy |
| 2 | BMY | Bristol-myers Squibb Co | +4.2% | NEW | New buy |
| 3 | JAZZ | Jazz Pharmaceuticals plc | +4.1% | NEW | New buy |
| 4 | IDXX | Idexx Laboratories Inc | +3.9% | NEW | New buy |
| 5 | UNH | Unitedhealth Group Inc | +3% | NEW | New buy |
| 6 | JANX | Janux Therapeutics Inc | +2.6% | NEW | New buy |
| 7 | AXSM | Axsome Therapeutics Inc | +2.4% | +172.31% | Add |
| 8 | CI | THE Cigna Group | +2.3% | NEW | New buy |
| 9 | WGS | Genedx Holdings CORP | +2% | NEW | New buy |
| 10 | NVO | Novo-nordisk A/s-spons Adr | +1.8% | +212.21% | Add |
| 11 | GERN | Geron CORP | +1.8% | NEW | New buy |
| 12 | EOLS | Evolus Inc | +1.7% | NEW | New buy |
| 13 | LIVN | LivaNova PLC | +1% | NEW | New buy |
| 14 | MDGL | Madrigal Pharmaceuticals Inc | +0.8% | +9.67% | Add |
| 15 | ✓ | Merus N V | +0.7% | +80.74% | Add |
| 16 | KRRO | Korro Bio Inc | +0.6% | +125.29% | Add |
| 17 | PRAX | Praxis Precision Medicines I | +0.6% | NEW | New buy |
| 18 | VRNA | Verona Pharma PLC - Adr | +0.3% | -23.53% | Trim |
| 19 | ✓ | Femasys Inc | — | — | Unchanged |
| 20 | ARGX | Argenx Se - Adr | -0.7% | -6.75% | Trim |
| 21 | TEVA | Teva Pharmaceutical-sp Adr | -0.8% | -12.07% | Trim |
| 22 | ✓ | Avadel Pharmaceuticals PLC ADR | -1% | +16.68% | Add |
| 23 | BRD1EUR | Mind Medicine Mindmed Inc | -1.1% | -50.64% | Trim |
| 24 | BHVN | Biohaven Ltd. | -1.2% | -27.42% | Trim |
| 25 | LEGN | Legend Biotech Corp-adr | -1.6% | +7.30% | Add |
| 26 | INSP | Inspire Medical Systems Inc | -1.9% | -0.42% | Trim |
| 27 | INSM | Insmed Inc | -2.5% | EXIT | Sold out |
| 28 | NTRA | Natera Inc | -3% | -36.16% | Trim |
| 29 | STVN | Stevanato Group S.p.A. | -3.9% | -39.94% | Trim |
| 30 | UTHR | United Therapeutics CORP | -4.7% | EXIT | Sold out |
| 31 | PCVX | Vaxcyte Inc | -7.4% | EXIT | Sold out |
| 32 | PFE | Pfizer Inc | -12% | EXIT | Sold out |
According to official SEC Form 13F filings, Tri Locum Partners LP reported a total U.S. public equity portfolio value of $813.2M across 28 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TEVA, ZBH, ARGX) accounted for 23.1% of total reported equity market value during Q4 2024.
Top New Position Initiated
ZBH
市值: $39.0M
Top Position Liquidated / Trimmed
PFE
前期市值: $50.2M
During Q4 2024, Tri Locum Partners LP's top holdings by market value included TEVA (11.1%)、ZBH (8.1%)、ARGX (7.4%). The largest single position, TEVA, represented 11.1% of total portfolio value.
In Q4 2024, Tri Locum Partners LP made 31 total portfolio adjustments, initiating 12 new buys, adding to 7 positions, trimming 8 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.